Turn Therapeutics (TTRX) Income towards Parent Company (2024 - 2026)

Turn Therapeutics' Income towards Parent Company history runs 3 years deep, the most recent figure standing at -$3.1 million for Q1 2026.

• On a quarterly basis, Income towards Parent Company fell 449.34% year-over-year to -$3.1 million in Q1 2026; TTM through Mar 2026 was -$14.2 million, a N/A change from a year earlier, with the FY2025 full-year figure at -$13.9 million, down 146.3% from the prior year.
• Income towards Parent Company eased to -$3.1 million in Q1 2026 per TTRX's latest filing, from -$2.9 million in the prior quarter.
• Across five years, Income towards Parent Company topped out at -$470237.0 in Q4 2024 and bottomed at -$7.6 million in Q3 2025.
• The 3-year median for Income towards Parent Company is -$2.0 million (2024), against an average of -$2.6 million.
• Across the five-year window, Income towards Parent Company sank 638.58% in 2025 and tumbled 449.34% in 2026, its largest moves.
• Year by year, Income towards Parent Company stood at -$470237.0 in 2024, then sank by 522.47% to -$2.9 million in 2025, then fell by 7.5% to -$3.1 million in 2026.
• Per Business Quant, the three latest TTRX Income towards Parent Company figures stand at -$3.1 million (Q1 2026), -$2.9 million (Q4 2025), and -$7.6 million (Q3 2025).